Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

House To Probe Presidential Oversight Of Agency Guidances, Regs

This article was originally published in The Gray Sheet

Executive Summary

Two House subcommittees are planning a joint hearing on amended 1Executive Order 12866, which institutionalizes the review of federal agency regulations and guidance documents by presidential appointees

You may also be interested in...



Congress Urged To Address Expanded OMB Role In Regulations, Guidances

The nonpartisan government watchdog group OMB Watch is urging Congress to take action against an executive order that increases the administration's influence over regulations and guidance documents issued by FDA and other agencies

Congress Urged To Address Expanded OMB Role In Regulations, Guidances

The nonpartisan government watchdog group OMB Watch is urging Congress to take action against an executive order that increases the administration's influence over regulations and guidance documents issued by FDA and other agencies

People In Brief

Azar resigns from government: HHS Deputy Secretary Alex Azar will step down Feb. 3 to explore potential opportunities in the private sector, the agency announces Jan. 17. Azar's resignation comes after more than five years of service at HHS, where he was general counsel from 2001-2005 before taking on his current role. No successor has been named. A White House nominee for the position must be confirmed by the Senate before taking office...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024486

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel